[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron Pharmaceuticals (REGN) shares tanked this morning as the biotech firm announced its highly anticipated Phase 3 trial evaluating an experimental skin cancer combination therapy failed to meet its primary endpoint. 

The late-stage trial REGN’s fianlimab (LAG-3 inhibitor), combined with its established immuno-therapy Libtayo, against Merck’s (MRK) blockbuster standard-of-care, Keytruda, in over 1,500 advanced melanoma patients. 

Fundamentals

See More
  • Market Capitalization, $K 73,818,992
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.30
  • Price/Sales 5.25
  • Price/Cash Flow 16.98
  • Price/Book 2.40

Options Overview Details

View History
  • Implied Volatility 31.13% (-6.26%)
  • Historical Volatility 40.29%
  • IV Percentile 8%
  • IV Rank 21.55%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 4) 20.32 (3.23%)
  • Put/Call Vol Ratio 1.33
  • Today's Volume 6,442
  • Volume Avg (30-Day) 2,230
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 38,602
  • Open Int (30-Day) 41,568
  • Expected Range 609.37 to 650.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.40
  • Number of Estimates 7
  • High Estimate $11.13
  • Low Estimate $6.29
  • Prior Year $10.72
  • Growth Rate Est. (year over year) -21.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
610.60 +3.12%
on 05/18/26
767.21 -17.93%
on 04/23/26
-120.89 (-16.11%)
since 04/17/26
3-Month
610.60 +3.12%
on 05/18/26
794.77 -20.77%
on 03/03/26
-162.48 (-20.51%)
since 02/18/26
52-Week
476.49 +32.15%
on 06/05/25
821.11 -23.31%
on 01/09/26
+35.36 (+5.95%)
since 05/16/25

Most Recent Stories

More News
Oil prices keep swinging, and so do stocks worldwide

Oil prices and stock markets worldwide swung with uncertainty about what will happen with the Iran war

NVDA : 222.32 (-1.33%)
D : 67.56 (+9.44%)
$SPX : 7,403.05 (-0.07%)
BSX : 55.92 (+6.15%)
$DOWI : 49,686.12 (+0.32%)
BRK : 193.01 (-0.41%)
REGN : 629.68 (-9.82%)
$IUXX : 28,994.37 (-0.45%)
NEE : 89.04 (-4.63%)
Stocks Settle Mixed as Iran War Remains Unresolved

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini...

MSTR : 166.63 (-6.08%)
AMAT : 413.57 (-5.28%)
AVGO : 420.71 (-1.05%)
SNDK : 1,333.01 (-5.30%)
D : 67.56 (+9.44%)
HIMS : 22.29 (-11.02%)
MBLY : 9.34 (-6.79%)
GLXY : 27.87 (-5.88%)
$IUXX : 28,994.37 (-0.45%)
COIN : 189.44 (-3.07%)
ASML : 1,472.39 (-1.96%)
ZNM26 : 109-110 (+0.30%)
Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

MRK : 112.56 (+1.06%)
REGN : 629.68 (-9.82%)
SNY : 43.54 (+1.99%)
Why Regeneron (REGN) Shares Are Trading Lower Today

Why Regeneron (REGN) Shares Are Trading Lower Today

REGN : 629.68 (-9.82%)
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky About Fraud Investigation

New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.")...

REGN : 629.68 (-9.82%)
Stocks Pressured by a Rebound in Crude Prices and Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%. June E-mini S&P futures...

MSTR : 166.63 (-6.08%)
AMAT : 413.57 (-5.28%)
AVGO : 420.71 (-1.05%)
SNDK : 1,333.01 (-5.30%)
D : 67.56 (+9.44%)
HIMS : 22.29 (-11.02%)
MBLY : 9.34 (-6.79%)
GLXY : 27.87 (-5.88%)
$IUXX : 28,994.37 (-0.45%)
COIN : 189.44 (-3.07%)
UNH : 391.13 (-0.69%)
ASML : 1,472.39 (-1.96%)
Stocks Mixed as Crude Oil Prices and Bond Yields Fall

The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. June E-mini S&P futures (ESM26...

ALK : 37.36 (+1.14%)
MSTR : 166.63 (-6.08%)
UAL : 92.55 (-0.32%)
D : 67.56 (+9.44%)
ADI : 418.58 (+0.26%)
HIMS : 22.29 (-11.02%)
MBLY : 9.34 (-6.79%)
GLXY : 27.87 (-5.88%)
$IUXX : 28,994.37 (-0.45%)
COIN : 189.44 (-3.07%)
UNH : 391.13 (-0.69%)
ZNM26 : 109-110 (+0.30%)
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Heliconâ„¢ Conjugates Across Multiple Therapeutic Areas

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform  Agreement provides for Parabilis to receive $125M...

REGN : 629.68 (-9.82%)
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the...

REGN : 629.68 (-9.82%)
Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Hikaru Kuribayashi, 17, receives $100,000 Top Award for his creation of a simulation program to understand complex folding at the world’s largest pre-college STEM competition. TARRYTOWN, N.Y....

REGN : 629.68 (-9.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 660.65
2nd Resistance Point 646.83
1st Resistance Point 638.25
Last Price 629.68
1st Support Level 615.85
2nd Support Level 602.03
3rd Support Level 593.45

See More

52-Week High 821.11
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Last Price 629.68
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.